Fixed dose combination dextromethorphan-bupropion: A hope for treatment resistant depression (TRD).
Ranjan Das, Rajarshi Chakravarty, Varaha V Gantait, Subir Bhattacharjee
Indian Journal of Psychiatry June 1, 2025 DOI: 10.4103/indianjpsychiatry_315_25 (opens in new tab)
Study at a glance
AI-extracted from the abstract| Characteristics | Case study Case report Peer reviewed |
|---|---|
| Sample size | 3 |
| Population | Patients with treatment-resistant depression |
| Intervention | Dextromethorphan-bupropion |
| Duration | 2 weeks |
| Topics | Depression |
| Keywords | Dextromethorphan-bupropion Treatment resistant depression Severe depression New approach Potential solution Standard medications |
| Citations | 4 |
| Key findings | Dextromethorphan-bupropion produced satisfactory response within two weeks in three cases of treatment-resistant depression. |
Abstract
Treatment resistant depression (TRD) has been identified as non-response to depression with adequate dose and trial of two antidepressant medications of different classes. Near about 30% depressive patients are TRD cases. Olanzapine-fluoxetine combination, rTMS, Intravenous ketamine and Electroconvulsive therapy have been till now studied in TRD. Dextromethorphan-bupropion is a newer antidepressant, which has been found to be effective, fast-acting, and well tolerated medicine for depression. We used this novel antidepressant in three cases of TRD, alone and with combination, and it showed satisfactory response within 2 weeks.